Alignment Healthcare, Inc.

Alignment Healthcare, Inc. (ALHC) Market Cap

Alignment Healthcare, Inc. has a market capitalization of $4.34B.

Financials based on reported quarter end 2025-12-31

Price: $21.22

0.40 (1.92%)

Market Cap: 4.34B

NASDAQ · time unavailable

CEO: John E. Kao

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2021-03-26

Website: https://www.alignmenthealthcare.com

Alignment Healthcare, Inc. (ALHC) - Company Information

Market Cap: 4.34B · Sector: Healthcare

Alignment Healthcare, Inc., a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada. It also coordinates and provides covered health care services, including professional, institutional, and ancillary services to members enrolled in certain benefit plans of unaffiliated Medicare Advantage Health Maintenance Organizations. The company was founded in 2013 and is based in Orange, California.

Analyst Sentiment

81%
Strong Buy

Based on 13 ratings

Analyst 1Y Forecast: $23.00

Average target (based on 3 sources)

Consensus Price Target

Low

$18

Median

$25

High

$30

Average

$25

Potential Upside: 15.5%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALIGNMENT HEALTHCARE INC (ALHC) — Investment Overview

🧩 Business Model Overview

Alignment Healthcare Inc. (ALHC) operates as a next-generation, technology-enabled Medicare Advantage (MA) organization. The company focuses on delivering healthcare to seniors, primarily through its proprietary Alignment Health Platform™, which integrates care delivery, population health management, and analytics. ALHC partners with a variety of healthcare providers, including primary care physicians, specialists, and hospitals, alongside leveraging deep data insights to proactively manage enrollee health and optimize outcomes. Through its full-risk model, ALHC assumes financial responsibility for delivering covered healthcare services within defined parameters, aiming to improve both cost efficiency and quality metrics. The company's approach is distinguished by a blend of technology-driven care coordination, personalized member engagement, and emphasis on social determinants of health tailored to vulnerable senior populations.

💰 Revenue Streams & Monetisation Model

Alignment Healthcare derives nearly all its revenue from capitated PMPM (per member per month) payments received under at-risk contracts with the Centers for Medicare & Medicaid Services (CMS), as well as partner health plans, under the Medicare Advantage program. In this model, ALHC receives a fixed amount per member from government entities, irrespective of actual medical costs incurred, incentivizing the use of preventive care and efficient health management. Revenue is driven by enrollment growth, risk-adjustment coding accuracy, and performance in CMS Star Ratings, with higher quality and outcomes offering incremental bonuses. ALHC may also receive shared savings or administrative fees through partnerships or delegated managed care agreements with provider groups and payors, though these represent a minority of total revenue. The company's monetization strategy is tightly linked to optimizing the health of its member population, lowering medical loss ratios, and driving operational efficiencies via its technology platform.

🧠 Competitive Advantages & Market Positioning

ALHC competes in the increasingly crowded Medicare Advantage space but has established several distinct competitive advantages: - **Proprietary Technology Infrastructure:** The Alignment Health Platform™ enables real-time data analytics and risk stratification, offering superior care coordination compared to legacy systems. This technological foundation supports scalable population health management. - **Integrated, Personalized Care Model:** ALHC’s “virtual first” strategy, including 24/7 concierge services and personalized care teams, results in high patient satisfaction and member retention. The focus on social determinants of health fosters improved outcomes, especially for high-risk or underserved populations. - **Ability to Manage Full Risk:** Unlike many small MA plans that struggle with medical cost management, ALHC’s demonstrated ability to operate at-capitation and manage medical spend positions it better for margin expansion as scale increases. - **Strong Relationships with Providers:** ALHC’s collaborative partnerships and value-based provider contracts deepen network integration and create mutual incentives for quality care. - **Focus on Underserved Regions:** The company often targets markets with demographic tailwinds and lower MA penetration, reducing direct competition with national incumbents.

🚀 Multi-Year Growth Drivers

Alignment Healthcare’s long-term growth prospects are underpinned by several secular trends and company-specific initiatives: - **Expansion of Medicare Advantage:** The senior population in the U.S. is projected to continue rising, with Medicare Advantage forecast to take a growing share of Medicare eligibles due to superior benefits and cost structures. - **Geographic and Product Expansion:** ALHC has significant runway to enter new states and counties, and to cross-sell additional plan types and supplemental benefits, serving broader and more diverse populations. - **Technology-Driven Cost Efficiencies:** Continuous investment in data science, automation, and machine learning capabilities supports better member risk assessment and proactive interventions, driving MLR improvement. - **Value-Based Care Adoption:** The policy and market shift towards value-based care and risk-sharing contract models aligns with ALHC’s full-risk approach, potentially opening new payer/provider partnerships. - **Demonstrated Outcomes and Quality Ratings:** Improving Star Ratings and member satisfaction not only drive CMS bonuses but also increase plan attractiveness, supporting organic enrollment growth.

⚠ Risk Factors to Monitor

Investors should remain alert to several key risk factors inherent to ALHC’s business model: - **Regulatory & Policy Risk:** The Medicare Advantage program is subject to frequent policy updates, including changes to payment structures, risk adjustment formulas, and quality incentive frameworks, which could materially impact revenue and margins. - **Execution Risk on Growth:** Geographic expansion and member growth entail significant operational complexity, and failure to execute could pressure profitability and dilute the brand. - **Medical Cost Management:** Difficulty in accurately predicting and controlling medical expenses, especially as the company scales into higher-acuity populations, could cause medical loss ratios to spike. - **Competition:** Increasing competition from national insurers, new MA entrants, and disruptive technology companies could lead to margin compression or higher acquisition costs for new members. - **Technology/Systemic Risk:** Dependence on proprietary technology platforms brings cybersecurity, data privacy, and systemic operational risks that require rigorous oversight. - **Dependence on CMS Star Ratings:** Deterioration in quality metrics or member outcomes could lead to reduced reimbursement, bonus eligibility, and plan attractiveness.

📊 Valuation & Market View

ALHC is generally valued using a combination of EV/revenue, EV/EBITDA, and price-to-earnings multiples relative to other managed care organizations and high-growth Medicare Advantage peers. The company has historically traded at a premium to diversified MCOs, justified by above-industry member growth, a differentiated care model, and underlying margin expansion potential. Market consensus views full-risk, tech-enabled MA organizations as long-term winners as the industry consolidates and as regulatory scrutiny accentuates the importance of high-quality, efficient care. Nevertheless, valuation is sensitive to execution on enrollment, sustainable MLR trends, and visibility into path-to-profitability at scale. Investors may expect volatility driven by regulatory headlines, MA bidding cycles, and competitive shifts within key geographies.

🔍 Investment Takeaway

Alignment Healthcare stands as a differentiated, technology-enabled Medicare Advantage disruptor with a proven ability to scale its full-risk, integrated care model. The company is positioned to compound growth through a combination of market expansion, superior member outcomes, and technology-driven operational efficiencies, benefitting from secular demographic and policy tailwinds. However, risks related to regulatory changes, execution, and medical cost control remain integral to the long-term thesis. Overall, ALHC represents a unique, high-growth exposure within the managed care universe, suited to investors seeking participation in the transformation of senior healthcare delivery—but success will depend on management’s ability to navigate a complex regulatory, competitive, and cost landscape while maintaining quality and innovation.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Headline (latest quarter ended 2025-12-31): Revenue $1.013B; Net Income -$11.0M; EPS -$0.0548. YoY (2025-12-31 vs 2024-12-31) was not determinable from the provided dataset (only 2025 quarters were supplied). QoQ (2025-12-31 vs 2025-09-30) Revenue rose slightly (+1.7%), while Net Income swung from profit to a loss (from +$3.7M to -$11.0M). Over the 4-quarter span, Revenue was choppy: $927M (2025-03-31) → $1.015B (2025-06-30) → $994M (2025-09-30) → $1.013B (2025-12-31). Net income similarly alternated between losses and gains, implying unstable profitability and margin pressure rather than a steady improvement trend. Cash flow quality looks mixed: Free Cash Flow was positive in 2 of the 4 quarters (notably 2025-09-30 at +$160.8M) but turned negative in the latest quarter (-$66.6M), with Operating Cash Flow at -$50.4M. Balance sheet resilience improved recently on asset scale but equity has been declining: total equity fell from $109.0M (2025-03-31) to $179.3M (2025-12-31) yet rose and fell along the way; net debt remains negative (net cash position) at -$239.9M, supporting liquidity. Shareholder returns are positive on price momentum (1Y +9.36%, 6M +21.21%), but there are no dividends and no buyback data provided. Analyst sentiment appears moderately constructive with a $24.5 consensus target vs ~$20.92 current (~+17%)."

Revenue Growth

Fair

Revenue is broadly flat with volatility: $927.0M (2025-03-31) to $1.013B (2025-12-31). QoQ latest quarter improved slightly (+1.7% from $993.7M to $1.013B), but there is no clear upward trajectory across the 4-quarter window.

Profitability

Caution

Net income is unstable: -$9.1M (2025-03-31) → +$15.7M (2025-06-30) → +$3.7M (2025-09-30) → -$11.0M (2025-12-31). Latest quarter saw a reversal from profit to loss; margins appear to be contracting/unstable.

Cash Flow Quality

Fair

FCF was positive in 2025-06-30 (+$21.1M) and 2025-09-30 (+$160.8M) but deteriorated to negative in 2025-12-31 (-$66.6M). Dividends are zero; no buyback data is provided, limiting confidence in cash-to-equity conversion.

Leverage & Balance Sheet

Positive

Balance sheet shows net cash: net debt is consistently negative (latest -$239.9M). Total assets increased to $1.066B (2025-12-31) from $895.6M (2025-03-31), suggesting resilience, though equity has fluctuated across quarters.

Shareholder Returns

Fair

Total shareholder return is primarily price-driven (no dividends). Price momentum is solid short-term (6M +21.21%), but 1Y is moderate (+9.36%), below the >20% threshold that would strongly boost the score.

Analyst Sentiment & Valuation

Neutral

Consensus target is $24.5 vs current ~$20.92 (implied upside ~17%). Analyst outlook appears supportive, though no earnings-quality improvement trend is evident given recent profit volatility.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered strong beats in Q4 2025 and highlighted disciplined margin expansion: full-year MBR improved 130 bps to 87.5% and adjusted EBITDA margin expanded 270 bps to 2.8%, with adjusted EBITDA of $11M in Q4 versus guidance of negative EBITDA. The tone in the prepared remarks is confident—“comfortable” about sustaining performance even in a flat-rate environment. However, analyst pressure in the Q&A centered on sustainability of profitability given reimbursement headwinds. The most candid detail was the MBR bridge: stripping out 2025’s sweep pickup, 2026 improvement is only ~10 bps apples-to-apples, while headwinds include B-28 phase-in (third phase) and a higher year-1 MBR new-member mix (Dual-Eligible/C-SNP/LIS). On rates, management expects CMS to “do the right thing,” but also acknowledges skin substitutes and utilization offsets are the key uncertainty for 2027. Net: optimism on operations/Stars, but the MBR upside is modest and contingent on policy/timing dynamics.

AI IconGrowth Catalysts

  • Health plan membership 236,300 in Q4 2025 (+25% YoY) driving $1.0B total revenue (+44% YoY)
  • Exceeding high end of profitability metrics guidance in Q4 2025
  • Clinical model visibility/control helped navigate V28 second phase redesign of Part D program and utilization pressure (industry-wide)
  • AEP January 2026 enrollment: 275,300 members (+31% YoY) with 23% growth in CA and >80% growth in ex-CA counties
  • Nearly 20% improvement to AEP voluntary disenrollment metric and ~80% of gross sales from plan switchers (proxy for “responsible growth”)

Business Development

  • Deepening relationships with broker partners and aligned provider partners in ex-California markets (no named partners/customers disclosed)
  • Star ratings as a growth lever: 5-star plan in North Carolina (3rd consecutive year), 2 plans in Nevada at 5-star, 4.5-star plan in Texas, and 4-star plan in Arizona

AI IconFinancial Highlights

  • Q4 2025 adjusted gross profit: $125M; adjusted MBR 87.7%
  • Q4 2025 adjusted EBITDA: $11M vs guidance range of -$9M to -$1M (solid outperformance)
  • Full-year 2025 revenue: $3.9B (+46% YoY)
  • Full-year 2025 adjusted gross profit: $495M; MBR 87.5% (+130 bps improvement YoY)
  • Full-year 2025 adjusted EBITDA: $110M; adjusted EBITDA margin 2.8% (+270 bps YoY margin expansion)
  • Q&A—2026 implied MBR at midpoint: 87.7%; apples-to-apples improvement cited as ~10 bps (excluding sweep pickup benefit from 2025)
  • 2025 sweep pickup benefit: ~$14M to full-year adjusted gross profit and EBITDA (~30 bps to consolidated MBR)
  • Guidance raise: FY2026 year-end membership guidance raised by 2,000 members at the midpoint vs Jan 8-K commentary
  • FY2026 guidance: membership 292,000–298,000; revenue $5.14B–$5.19B; adjusted gross profit $615M–$650M (MBR implied midpoint 87.7%); adjusted EBITDA $133M–$163M

AI IconCapital Funding

  • Cash and investments: $604M at year-end 2025
  • Post-quarter: closed $200M revolving credit facility; company does not expect to draw in the near term

AI IconStrategy & Ops

  • AI deployment gated by foundational prerequisites: unified data architecture and AVA validation; workflow documentation and training readiness; plan to complete these by midyear 2026 before deploying agentic AI use cases
  • Stratification model revisiting within AVA, targeting Care Anywhere members: ~10% of population driving ~78% of spend
  • Planned reinvestment of operating efficiency savings into clinical model, new market activities, and technology infrastructure; focus on administrative AI workflows (member services highlighted as an early savings area)
  • Operating efficiency: adjusted SG&A as % of revenue improved ~140 bps (11.1% in 2024 to 9.7% in 2025)

AI IconMarket Outlook

  • 2026 outlook (full-year): adjusted EBITDA $133M–$163M (midpoint consistent with consensus ~ $145M described by management)
  • Q1 2026 guidance: membership 281,000–285,000; revenue $1.21B–$1.23B; adjusted gross profit $138M–$148M; adjusted EBITDA $26M–$36M
  • 2027 advanced rate notice: management characterized it as “relatively flat” net; expects benchmark cost growth in FFS partially offsets by policy adjustments (including skin substitutes); expects STARS payment advantages in 2027 with 100% of members/plans at 4 stars or above

AI IconRisks & Headwinds

  • 2026 MBR improvement skepticism: management attributed why MBR may not improve more despite ~10 bps apples-to-apples improvement—headwinds include: (1) continuing B-28 phase-in/third phase, (2) new-member mix disproportionately represented by Dual-Eligible, C-SNP eligible, and LIS (higher year-1 MBR) while also being management’s “sweet spot,” and (3) no 2026 assumption for sweep pickup from new members (sweep was ~$14M benefit in 2025 / ~30 bps to MBR)
  • V28: second phase redesign of Part D program and broad utilization pressures across MA industry (navigated in 2025; still a noted disruption backdrop)
  • Utilization trend uncertainty for 2027/“rate universe” dominated by CMS program integrity changes and specific policy items (skin substitutes; unlinked chart review treatment)
  • Chart review policy: management stated exposure is limited—~1% of total HCC value from chart reviews; even smaller subset from unlinked chart reviews; they support excluding unlinked chart reviews from risk scoring and believe linked diagnosis support will be ensured over time
  • Q&A on “80k” metric: health plan medical cost proxy may tick up due to mix (dual-eligible/special needs), despite trend being properly managed; seasonality noted (Q1 usually higher)

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ALHC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ALHC)

© 2026 Stock Market Info — Alignment Healthcare, Inc. (ALHC) Financial Profile